Join to access to all OVN content. Join for Free

Results for 'RB'

...
OVN Avatar Forbes Books Press Release Official
New Book Unites Oncology’s Brightest Minds To Innovate Cancer Cures

Sep 8th • 5 mins read

...
Partner Avatar Tom Caravela
Interview Differentiator-Be a Story Teller

Mar 21st • 1 min read

...
Partner Avatar Tom Caravela
12 Interview Techniques to Help Land Your Next Job

May 11th • 1 min read

...
Partner Avatar Tom Caravela
Job Search Checklist for Aspiring Medical Science Liaisons

May 16th • 2 mins read

...
Partner Avatar Tom Caravela
10 Ways to Make an Impact on a Phone Interview

Apr 8th • 1 min read

...
Partner Avatar Tom Caravela
INTENTION: The Key to Achieving Your Goals

Jan 20th • 1 min read

...
Partner Avatar Bridget Rasmusson
Positioning Yourself to Become an MSL in 2022

Dec 20th • 10 mins read

...
OVN Avatar Paulo J. Oliveira, Ana M. Urbano
“Oncometabolism: The switchboard of cancer: An editorial”

Jan 31st • 1 min read

...
OVN Avatar Carrie Printz
First person profile: William Sellers, MD

Nov 5th • 2 mins read

...
OVN Avatar J. Remon, R. García-Campelo, E. de Álava, R. Vera, J. L. Rodríguez-Peralto, Á. Rodríguez-Lescure, B. Bellosillo, P. Garrido, F. Rojo & R. Álvarez-Alegret
Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

Sep 25th • 17 mins read

...
OVN Avatar Carrie Printz
Precision medicine for pediatric cancers lags behind that for adult cancers: Citing hurdles in clinical trial recruitment and drug development, researchers are exploring ways to close gaps

Jan 8th • 2 mins read

...
OVN Avatar Mariam A. Ahmed, Chirag Patel, Nicole Drezner, Whitney Helms, Weiwei Tan, Daria Stypinski
Pivotal Considerations for Optimal Deployment of Healthy Volunteers in Oncology Drug Development

Oct 30th • 20 mins read

...
OVN Avatar J. Remon, R. García-Campelo, E. de Álava, R. Vera, J. L. Rodríguez-Peralto, Á. Rodríguez-Lescure, B. Bellosillo, P. Garrido, F. Rojo & R. Álvarez-Alegret
Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

Sep 25th • 16 mins read

...
OVN Avatar Gregory S. Calip, PharmD, MPH, PhD, Ivy P. Altomare, MD, Jenny S. Guadamuz, MSPH, PhD
Evaluating External Validity of Oncology Biosimilar Safety Studies

Apr 5th • 2 mins read

...
OVN Avatar Francesco Cerisoli, PhD, Farzad Ali, MSc, Tamás Bereczky, MA, PhD, Natacha Bolaños, BS, Lars Bullinger, MD, Sujith Dhanasiri, MPhil, MSc, James Gallagher, PhD, Sonia García Pérez, MSc, Jan Geissler, MiBA, Yann Guillevic, DEA, Kathryn Harrison, PhD, Anasta
Building a Healthcare Alliance for Resourceful Medicine Offensive Against Neoplasms in Hematology Added Value Framework for Hematologic Malignancies: A Comparative Analysis of Existing Tools

May 16th • 12 mins read

...
OVN Avatar Jonathan H Seltzer MD, MBA, MA, Gary Gintant PhD, Laleh Amiri-Kordestani MD, Jack Singer MD, Luana Pesco Koplowitz MD, PhD, Javid J Moslehi MD, Ana Barac MD, PhD, Anthony F. Yu MD
Assessing cardiac safety in oncology drug development

Jun 11th • 12 mins read

...
OVN Avatar Talal Hilal, MD; Mohamad Bassam Sonbol, MD; Vinay Prasad, MD, MPH
Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration

May 1st • 15 mins read

...
OVN Avatar Ajaikumar B Kunnumakkara kunnumakkara@iitg.ac.in, Devivasha Bordoloi, Bethsebie Lalduhsaki Sailo, Nand Kishor Roy, Krishan Kumar Thakur, Kishore Banik, Mehdi Shakibaei, Subash C Gupta, and Bharat B Aggarwal
Cancer drug development: The missing links

Apr 17th • 20 mins read

...
OVN Avatar Dylan V. Neel, MPhil, David S. Shulman, MD, and Steven G. DuBois, MD
Timing of first-in-child trials of FDA-approved oncology drugs

Mar 17th • 10 mins read

...
Partner Avatar Envision Pharma Group
AI-powered real-world evidence: Strategically enhancing value and access

Aug 21st • 5 mins read

Related Topics

Loading...